ORIC Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 9.24 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 957.75M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutat...